Your browser doesn't support javascript.
loading
The deubiquitylase USP9X controls ribosomal stalling.
Clancy, Anne; Heride, Claire; Pinto-Fernández, Adán; Elcocks, Hannah; Kallinos, Andreas; Kayser-Bricker, Katherine J; Wang, Weiping; Smith, Victoria; Davis, Simon; Fessler, Shawn; McKinnon, Crystal; Katz, Marie; Hammonds, Tim; Jones, Neil P; O'Connell, Jonathan; Follows, Bruce; Mischke, Steven; Caravella, Justin A; Ioannidis, Stephanos; Dinsmore, Christopher; Kim, Sunkyu; Behrens, Axel; Komander, David; Kessler, Benedikt M; Urbé, Sylvie; Clague, Michael J.
Afiliación
  • Clancy A; Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Heride C; Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Pinto-Fernández A; Cancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, UK.
  • Elcocks H; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Kallinos A; Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Kayser-Bricker KJ; Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Wang W; FORMA Therapeutics, Watertown, MA.
  • Smith V; FORMA Therapeutics, Watertown, MA.
  • Davis S; Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Fessler S; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • McKinnon C; FORMA Therapeutics, Watertown, MA.
  • Katz M; FORMA Therapeutics, Watertown, MA.
  • Hammonds T; FORMA Therapeutics, Watertown, MA.
  • Jones NP; Cancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, UK.
  • O'Connell J; Cancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, UK.
  • Follows B; FORMA Therapeutics, Watertown, MA.
  • Mischke S; FORMA Therapeutics, Watertown, MA.
  • Caravella JA; FORMA Therapeutics, Watertown, MA.
  • Ioannidis S; FORMA Therapeutics, Watertown, MA.
  • Dinsmore C; FORMA Therapeutics, Watertown, MA.
  • Kim S; FORMA Therapeutics, Watertown, MA.
  • Behrens A; FORMA Therapeutics, Watertown, MA.
  • Komander D; Adult Stem Cell Laboratory, Francis Crick Institute, London, UK.
  • Kessler BM; Ubiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
  • Urbé S; Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Clague MJ; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
J Cell Biol ; 220(3)2021 03 01.
Article en En | MEDLINE | ID: mdl-33507233
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Ribosomas / Ubiquitina Tiolesterasa / Ubiquitinación Límite: Humans Idioma: En Revista: J Cell Biol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Ribosomas / Ubiquitina Tiolesterasa / Ubiquitinación Límite: Humans Idioma: En Revista: J Cell Biol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido